文献速递胸部肿瘤放疗放疗物理与技术

放射保护剂BIO 300口服混悬液用于接受同步放化疗的非小细胞肺癌患者的多中心1b/2a期临床试验

Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients With Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-08-29

这项多中心、开放标签、单臂、剂量递增1b/2a期研究纳入21例新诊断II-IV期非小细胞肺癌患者,在60-70/1.8-2.0 Gy放疗及每周紫杉醇/卡铂同步化疗期间口服BIO 300(500、1000、1500 mg/d)。未报告剂量限制性毒性,BIO 300相关不良事件均为轻中度,未达到最大耐受剂量;血清转化生长因子β1呈剂量依赖性下降,肿瘤缓解率65%(完全缓解率20%)。

要点

  • BIO 300三个剂量队列均未报告剂量限制性毒性,未达到最大耐受剂量。
  • BIO 300相关不良事件(n=11)均为轻中度,以胃肠道反应为主(n=7)。
  • 肿瘤缓解率65%,完全缓解率20%,无患者最佳总体疗效为进展。

核心结论

  • 低毒性发生率、药效学结果及肿瘤缓解率支持进一步研究BIO 300作为有效放射保护剂。

研究设计与样本

  • 多中心、开放标签、单臂、剂量递增1b/2a期研究,纳入21例新诊断II-IV期非小细胞肺癌患者,计划接受60-70/1.8-2.0 Gy放疗及每周紫杉醇/卡铂同步化疗。
  • BIO 300口服混悬液(合成金雀异黄素纳米混悬液)按队列1 500 mg/d、队列2 1000 mg/d、队列3 1500 mg/d自我给药,每日一次,于同步放化疗开始前2-7天启动并持续至放疗结束。
  • 主要终点为归因于BIO 300的急性剂量限制性毒性;次要终点包括药代动力学、药效动力学、总体毒性、生活质量、局部缓解率和生存。

主要发现

  • 21例受试者入组,未报告剂量限制性毒性;BIO 300给药未改变化疗药代动力学。
  • 不良事件不呈剂量依赖性;归因于BIO 300的不良事件(n=11)均为轻中度(1级n=9;2级n=2),以胃肠道反应为主(n=7)。
  • 各队列间观察到血清转化生长因子β1水平呈剂量依赖性下降。
  • 患者报告的生活质量和体重在研究期间基本稳定。
  • 无患者最佳总体疗效为进展,肿瘤缓解率65%(完全缓解率20%)。

关键数值与推荐

  • 基于安全性分析,BIO 300的最大耐受剂量未达到。
  • BIO 300相关不良事件严重程度:1级n=9,2级n=2。

临床怎么用

  • 原文结论支持进一步研究BIO 300作为有效放射保护剂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation therapy is part of the standard treatment regimen for non-small cell lung cancer (NSCLC). Although radiation therapy is an effective tool to manage NSCLC, it can be associated with significant dose-limiting toxicities. These toxicities can lead to treatment interruption or early termination and worsening clinical outcomes in addition to reductions in patient quality of life. Based on preclinical efficacy for radioprotection of normal tissues, we evaluated the clinical utility of BIO 300 Oral Suspension (BIO 300; synthetic genistein nanosuspension) in patients with NSCLC. METHODS AND MATERIALS: In this multicenter, open-label, single-arm, ascending dose phase 1b/2a study, patients were enrolled with newly diagnosed stage II-IV NSCLC planned for 60 to 70/1.8-2.0 Gy radiation therapy and concurrent weekly paclitaxel/carboplatin. Oral BIO 300 (cohort 1, 500 mg/d; cohort 2, 1000 mg/d; cohort 3, 1500 mg/d) was self-administered once daily starting 2 to 7 days before initiating concurrent chemoradiotherapy and continued until the end of radiation therapy. The primary endpoint was acute dose-limiting toxicities attributable to BIO 300. Secondary outcomes included pharmacokinetics, pharmacodynamics, overall toxicity profile, quality of life, local response rate, and survival. RESULTS: Twenty-one participants were enrolled. No dose-limiting toxicities were reported. BIO 300 dosing did not alter chemotherapy pharmacokinetics. Adverse events were not dose-dependent, and those attributable to BIO 300 (n = 11) were all mild to moderate in severity (grade 1, n = 9; grade 2, n = 2) and predominantly gastrointestinal (n = 7). A dose-dependent decrease in serum transforming growth factor β1 levels was observed across cohorts. Based on safety analysis, the maximum tolerated dose of BIO 300 was not met. Patient-reported quality of life and weight were largely stable throughout the study period. No patient had progression as their best overall response, and a 65% tumor response rate was achieved (20% complete response rate). CONCLUSIONS: The low toxicity rates, along with the pharmacodynamic results and tumor response rates, support further investigation of BIO 300 as an effective radioprotector.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Simone CB, Serebrenik AA, Gore EM, et al. Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients With Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2023. PMID: 37652301. doi:10.1016/j.ijrobp.2023.08.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。